The management of locally advanced prostate cancer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The current management of locally advanced prostate cancer generally involves treatment with radiotherapy, hormone therapy or a combination of both. Of particular importance when choosing the type and duration of treatment is the patient's risk category, which predicts the risk of subclinical metastases based on prostate-specific antigen level, Gleason score and tumor stage. A breakout group at the PROstart 2002 workshop, charged with discussing this topic, concluded that hormone therapy is a recommended component of disease management and may improve survival, and that radiotherapy should be combined with neoadjuvant and or adjuvant hormone therapy.

Original languageEnglish (US)
JournalProstate Cancer and Prostatic Diseases
Volume5
Issue numberSUPPL. 2
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Hormones
Radiotherapy
Therapeutics
Neoplasm Grading
Prostate-Specific Antigen
Disease Management
Neoplasm Metastasis
Education
Survival
Neoplasms

Keywords

  • Hormone therapy
  • Locally advanced prostate cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

The management of locally advanced prostate cancer. / Valicenti, Richard K.

In: Prostate Cancer and Prostatic Diseases, Vol. 5, No. SUPPL. 2, 2002.

Research output: Contribution to journalArticle

@article{905ea2e0acc24fa89d2cfe0771b3a6e0,
title = "The management of locally advanced prostate cancer",
abstract = "The current management of locally advanced prostate cancer generally involves treatment with radiotherapy, hormone therapy or a combination of both. Of particular importance when choosing the type and duration of treatment is the patient's risk category, which predicts the risk of subclinical metastases based on prostate-specific antigen level, Gleason score and tumor stage. A breakout group at the PROstart 2002 workshop, charged with discussing this topic, concluded that hormone therapy is a recommended component of disease management and may improve survival, and that radiotherapy should be combined with neoadjuvant and or adjuvant hormone therapy.",
keywords = "Hormone therapy, Locally advanced prostate cancer, Radiotherapy",
author = "Valicenti, {Richard K}",
year = "2002",
doi = "10.1038/sj.pcan.4500620",
language = "English (US)",
volume = "5",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "SUPPL. 2",

}

TY - JOUR

T1 - The management of locally advanced prostate cancer

AU - Valicenti, Richard K

PY - 2002

Y1 - 2002

N2 - The current management of locally advanced prostate cancer generally involves treatment with radiotherapy, hormone therapy or a combination of both. Of particular importance when choosing the type and duration of treatment is the patient's risk category, which predicts the risk of subclinical metastases based on prostate-specific antigen level, Gleason score and tumor stage. A breakout group at the PROstart 2002 workshop, charged with discussing this topic, concluded that hormone therapy is a recommended component of disease management and may improve survival, and that radiotherapy should be combined with neoadjuvant and or adjuvant hormone therapy.

AB - The current management of locally advanced prostate cancer generally involves treatment with radiotherapy, hormone therapy or a combination of both. Of particular importance when choosing the type and duration of treatment is the patient's risk category, which predicts the risk of subclinical metastases based on prostate-specific antigen level, Gleason score and tumor stage. A breakout group at the PROstart 2002 workshop, charged with discussing this topic, concluded that hormone therapy is a recommended component of disease management and may improve survival, and that radiotherapy should be combined with neoadjuvant and or adjuvant hormone therapy.

KW - Hormone therapy

KW - Locally advanced prostate cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0036393253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036393253&partnerID=8YFLogxK

U2 - 10.1038/sj.pcan.4500620

DO - 10.1038/sj.pcan.4500620

M3 - Article

C2 - 12496990

AN - SCOPUS:0036393253

VL - 5

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - SUPPL. 2

ER -